Replies to post #111629 on Sunshine Biopharma Inc (SBFM)

[TraderAI]

Yup. If they can get Canada’s leading CPA firm to say hey SBFM is worth a billion bucks, you’d think they could do better job with all this

[hssbwwmp]

Proper News would be that SBFM has received approval from the FDA for an IND study (see requirements below) and has a start date for the study. This would be an excellent update to what was reported on May 26: "SBFM is reporting steps to begin an investigational new drug (IND) study of an anticancer drug the oncology-focused biopharmaceutical company is developing — and recently announced that two of its newly designed mRNA molecules are effective at destroying cancer cells grown in culture. The use of mRNA could prove a powerful ally in the fight against cancer."


IND Application Requirements: The IND application must contain information in three broad areas:

Animal Pharmacology and Toxicology Studies - Preclinical data to permit an assessment as to whether the product is reasonably safe for initial testing in humans. Also included are any previous experience with the drug in humans (often foreign use).

Manufacturing Information - Information pertaining to the composition, manufacturer, stability, and controls used for manufacturing the drug substance and the drug product. This information is assessed to ensure that the company can adequately produce and supply consistent batches of the drug.

Clinical Protocols and Investigator Information - Detailed protocols for proposed clinical studies to assess whether the initial-phase trials will expose subjects to unnecessary risks. Also, information on the qualifications of clinical investigators--professionals (generally physicians) who oversee the administration of the experimental compound--to assess whether they are qualified to fulfill their clinical trial duties. Finally, commitments to obtain informed consent from the research subjects, to obtain review of the study by an institutional review board (IRB), and to adhere to the investigational new drug regulations.

Once the IND is submitted, the sponsor must wait 30 calendar days before initiating any clinical trials. During this time, FDA has an opportunity to review the IND for safety to assure that research subjects will not be subjected to unreasonable risk.